miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.

McGirt LY, Adams CM, Baerenwald DA, Zwerner JP, Zic JA, Eischen CM
J Invest Dermatol. 2014 134 (4): 1101-1107

PMID: 24304814 · PMCID: PMC3961555 · DOI:10.1038/jid.2013.461

The pathogenesis of the cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), is unclear. MicroRNA (miRNA) are small noncoding RNAs that target mRNA leading to reduced mRNA translation. Recently, specific miRNA were shown to be altered in CTCL. We detected significantly reduced expression of miR-223 in early-stage MF skin, and further decreased levels of miR-223 in advanced-stage disease. CTCL peripheral blood mononuclear cells and cell lines also had reduced miR-223 as compared with controls. Elevated expression of miR-223 in these cell lines reduced cell growth and clonogenic potential, whereas inhibition of miR-223 increased cell numbers. Investigations into putative miR-223 targets with oncogenic function, including E2F1 and MEF2C, and the predicted miR-223 target, TOX, revealed that all three were targeted by miR-223 in CTCL. E2F1, MEF2C, and TOX proteins were decreased with miR-223 overexpression, whereas miR-223 inhibition led to increased protein levels in CTCL. In addition, we showed that the 3'-UTR of TOX mRNA was a genuine target of miR-223. Therefore, reduced levels of miR-223 in MF/CTCL lead to increased expression of E2F1, MEF2C, and TOX, which likely contributes to the development and/or progression of CTCL. Thus, miR-223 and its targets may be useful for the development of new therapeutics for MF/CTCL.

MeSH Terms (18)

3' Untranslated Regions Animals Biopsy Cell Line, Tumor Cell Proliferation Cell Survival Disease Progression Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Leukocytes, Mononuclear Lymphoma, T-Cell, Cutaneous Mice MicroRNAs Mycosis Fungoides NIH 3T3 Cells Proto-Oncogenes Skin

Connections (1)

This publication is referenced by other Labnodes entities:

Links